AGY Stock Overview
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Allergy Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.029 |
| 52 Week High | UK£0.039 |
| 52 Week Low | UK£0.008 |
| Beta | 1.34 |
| 1 Month Change | 5.56% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -87.05% |
| 5 Year Change | -69.19% |
| Change since IPO | -96.17% |
Recent News & Updates
Shareholder Returns
| AGY | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 8.3% | 2.2% |
| 1Y | n/a | 4.9% | 0.9% |
Return vs Industry: Insufficient data to determine how AGY performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AGY performed against the UK Market.
Price Volatility
| AGY volatility | |
|---|---|
| AGY Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AGY's share price has been volatile over the past 3 months.
Volatility Over Time: AGY's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 612 | Manuel Llobet | www.allergytherapeutics.com |
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut.
Allergy Therapeutics plc Fundamentals Summary
| AGY fundamental statistics | |
|---|---|
| Market cap | UK£135.84m |
| Earnings (TTM) | -UK£50.22m |
| Revenue (TTM) | UK£53.26m |
2.6x
P/S Ratio-2.7x
P/E RatioIs AGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGY income statement (TTM) | |
|---|---|
| Revenue | UK£53.26m |
| Cost of Revenue | UK£25.28m |
| Gross Profit | UK£27.98m |
| Other Expenses | UK£78.20m |
| Earnings | -UK£50.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 52.54% |
| Net Profit Margin | -94.29% |
| Debt/Equity Ratio | 6.0% |
How did AGY perform over the long term?
See historical performance and comparison